Another study by Narcelli et al. showed that treatment using the NAMPT inhibitor FK866 in combination with cisplatin treatment reduces tumor growth, delays tumor relapse, and improves the survival outcomes of cisplatin-treated epithelial ovarian cancer (EOC) in pre-clinical models [109]. The gene discussed is NAMPT; the disease is ovarian carcinoma.